header logo image


Page 3«..2345..1020..»

Archive for the ‘Eye Sight & Vision’ Category

Here’s how eye exams can reveal several health conditions beyond your sight – The Record (New Westminster)

Friday, December 22nd, 2023

Here's how eye exams can reveal several health conditions beyond your sight  The Record (New Westminster)

Go here to see the original:
Here's how eye exams can reveal several health conditions beyond your sight - The Record (New Westminster)

Read More...

At Bread for the Citys vision clinic, patients can see clearly now – The Washington Post

Wednesday, December 13th, 2023

At Bread for the Citys vision clinic, patients can see clearly now  The Washington Post

Excerpt from:
At Bread for the Citys vision clinic, patients can see clearly now - The Washington Post

Read More...

SightCare Reviews – Is Official Website for Sight Care Legit to Try or Scam (2024) | Vashon-Maury Island Beachcomber – Vashon-Maury Island Beachcomber

Wednesday, December 13th, 2023

SightCare Reviews - Is Official Website for Sight Care Legit to Try or Scam (2024) | Vashon-Maury Island Beachcomber  Vashon-Maury Island Beachcomber

Here is the original post:
SightCare Reviews - Is Official Website for Sight Care Legit to Try or Scam (2024) | Vashon-Maury Island Beachcomber - Vashon-Maury Island Beachcomber

Read More...

The Benefits of Donning Prescription Sunglasses for Vision Correction and Protection – Anti Aging News

Wednesday, December 13th, 2023

The Benefits of Donning Prescription Sunglasses for Vision Correction and Protection  Anti Aging News

More:
The Benefits of Donning Prescription Sunglasses for Vision Correction and Protection - Anti Aging News

Read More...

Vision Pro training of Apple retail store employees to start soon – BGR

Wednesday, December 13th, 2023

Vision Pro training of Apple retail store employees to start soon  BGR

See the original post:
Vision Pro training of Apple retail store employees to start soon - BGR

Read More...

6 Best Vitamins and Supplements for Healthy Eyes – CNET

Wednesday, December 13th, 2023

6 Best Vitamins and Supplements for Healthy Eyes  CNET

Here is the original post:
6 Best Vitamins and Supplements for Healthy Eyes - CNET

Read More...

Eye Health: How to Protect Eyes From Digital Strain, Vision Loss and More? 5 Tips – India.com

Wednesday, December 13th, 2023

Eye Health: How to Protect Eyes From Digital Strain, Vision Loss and More? 5 Tips  India.com

Visit link:
Eye Health: How to Protect Eyes From Digital Strain, Vision Loss and More? 5 Tips - India.com

Read More...

How to watch the solar eclipse without damaging your eyesight – WATE 6 On Your Side

Monday, October 16th, 2023

How to watch the solar eclipse without damaging your eyesight  WATE 6 On Your Side

See the rest here:
How to watch the solar eclipse without damaging your eyesight - WATE 6 On Your Side

Read More...

Can Optical Illusions Improve Vision? Know The Best One That Benefits Eyesight – Times Now

Wednesday, May 17th, 2023

Can Optical Illusions Improve Vision? Know The Best One That Benefits Eyesight  Times Now

Go here to read the rest:
Can Optical Illusions Improve Vision? Know The Best One That Benefits Eyesight - Times Now

Read More...

Motus GI Announces Executive Leadership Restructuring and Additional Cost Saving Initiatives to Support Near-Term Milestones

Saturday, April 15th, 2023

FORT LAUDERDALE, Fla. , April 13, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company focused on improving endoscopic outcomes and experiences, today announced executive changes and restructuring as part of its strategy to reduce operating costs while supporting key value creation drivers, including ongoing R&D efforts to bring Pure-Vu Upper GI, and an enhanced Lower GI platform to market, while continuing to support existing customer base and target pipeline opportunities in contracted health systems. As part of the executive changes, Mr. Moran has elected to step down as Chief Executive Officer (CEO) of the Company to pursue other business opportunities. Mr. Moran will remain on the Board and has been appointed Chairman of the Board, succeeding David Hochman, who will remain an independent director, effective immediately. Mark Pomeranz, the Company’s current President, Chief Operating Officer, and director and former CEO of the Company, has been appointed as the Company’s CEO, effective immediately. Mr. Moran will work closely with Mr. Pomeranz to support a smooth transition and maintain key relationships with Motus GI’s stakeholders.

Continue reading here:
Motus GI Announces Executive Leadership Restructuring and Additional Cost Saving Initiatives to Support Near-Term Milestones

Read More...

Revolution Medicines to Participate in 22nd Annual Needham Healthcare Conference

Saturday, April 15th, 2023

REDWOOD CITY, Calif., April 13, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will be the featured speaker in a fireside chat at the 22nd Annual Needham Healthcare Conference. The conference will take place April 17-20, 2023.

Go here to see the original:
Revolution Medicines to Participate in 22nd Annual Needham Healthcare Conference

Read More...

GENFIT Reports Full-Year 2022 Financial Results and Provides Corporate Update

Saturday, April 15th, 2023

Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); April 13, 2023 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases characterized by high unmet medical needs, today announced annual financial results for the year ended December 31, 2022. A summary of the consolidated financial statements is included further below.

Excerpt from:
GENFIT Reports Full-Year 2022 Financial Results and Provides Corporate Update

Read More...

Kane Biotech to Release Fourth Quarter and Full Year 2022 Financial Results on April 20, 2023 – Conference Call to Follow

Saturday, April 15th, 2023

WINNIPEG, Manitoba, April 13, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, will announce its fourth quarter and full year 2022 financial results after market close on Thursday, April 20, 2023.

See the article here:
Kane Biotech to Release Fourth Quarter and Full Year 2022 Financial Results on April 20, 2023 – Conference Call to Follow

Read More...

Biomea Fusion To Present Two Preclinical Posters at the 114th AACR Annual Meeting

Saturday, April 15th, 2023

REDWOOD CITY, Calif., April 13, 2023 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”)(Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, today announced the upcoming presentation of two preclinical abstracts at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida from April 14-19, 2023.

Read the rest here:
Biomea Fusion To Present Two Preclinical Posters at the 114th AACR Annual Meeting

Read More...

Cabaletta Bio to Present at the 22nd Annual Needham Virtual Healthcare Conference

Saturday, April 15th, 2023

PHILADELPHIA, April 13, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that Steven Nichtberger, M.D., Chief Executive Officer, will present a company presentation at the 22nd Annual Needham Virtual Healthcare Conference on Thursday, April 20, 2023 at 9:30 a.m. ET.

More here:
Cabaletta Bio to Present at the 22nd Annual Needham Virtual Healthcare Conference

Read More...

Syneos Health Schedules First Quarter 2023 Earnings Call for Wednesday, May 10th, 2023

Saturday, April 15th, 2023

MORRISVILLE, N.C., April 13, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), a leading fully integrated biopharmaceutical solutions organization, will release its first quarter 2023 financial results on Wednesday, May 10th, 2023, prior to its earnings call at 8:00 a.m. ET.

Continued here:
Syneos Health Schedules First Quarter 2023 Earnings Call for Wednesday, May 10th, 2023

Read More...

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Saturday, April 15th, 2023

SAN DIEGO, April 13, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on April 10, 2023, the Compensation Committee of its Board of Directors granted inducement equity grants to five new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 30,000 shares of its common stock. These inducement RSUs are subject to the terms of Travere’s 2018 Equity Incentive Plan (“2018 Plan”) but were granted outside of the 2018 Plan and were granted as inducements material to the new employees entering into employment with Travere in accordance with Nasdaq Listing Rule 5635(c)(4).

Read this article:
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Read More...

Oncternal Therapeutics Participating in Oppenheimer & Co.’s Virtual Fireside Chat: Discussion of ROR1 CAR T Cell Therapy in Hematological…

Saturday, April 15th, 2023

SAN DIEGO, April 13, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that two key industry opinion leaders and management will participate in Oppenheimer & Co.’s Virtual Fireside Chat: Discussion of ROR1 CAR-T Cell Therapy in Hematological Malignancies and Solid Tumors on Tuesday, April 18, 2023 at 1:30 p.m. EDT.

View original post here:
Oncternal Therapeutics Participating in Oppenheimer & Co.’s Virtual Fireside Chat: Discussion of ROR1 CAR T Cell Therapy in Hematological...

Read More...

Alvotech Provides Regulatory Update on AVT02 Biologics License Application

Saturday, April 15th, 2023

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for Alvotech’s Biologics License Application (BLA) for AVT02, a high-concentration biosimilar candidate for Humira® (adalimumab). The CRL noted that certain deficiencies, which were conveyed following the FDA’s reinspection of the company’s Reykjavik facility that concluded on March 17, 2023, must be satisfactorily resolved before the application can be approved.  No other deficiencies in the application were noted by the FDA.  Alvotech provided the FDA comprehensive responses to the inspection observations on April 3, 2023, and is awaiting communication from the agency assessing those responses.

View post:
Alvotech Provides Regulatory Update on AVT02 Biologics License Application

Read More...

Vivoryon Therapeutics N.V. to Report Full Year 2022 Financial Results and Operational Progress on April 19, 2023

Saturday, April 15th, 2023

Vivoryon Therapeutics N.V. to Report Full Year 2022 Financial Results and Operational Progress on April 19, 2023

Original post:
Vivoryon Therapeutics N.V. to Report Full Year 2022 Financial Results and Operational Progress on April 19, 2023

Read More...

Page 3«..2345..1020..»


2024 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick